First new-drug approval in a decade for ANCA-associated vasculitis tackles steroid-toxicity
Featured

First new-drug approval in a decade for ANCA-associated vasculitis tackles steroid-toxicity

Read More
Featured

Getting steroid sparing in the label: Measuring what matters in a Target Product Profile (TPP)

Steroid sparing and steroid avoidance have become important issues in modern medicine due to the toxic side effects of many common corticosteroid therapies used to treat conditions ranging from ...

Read More
James T. Rosenbaum, MD

In conversation with... James T. Rosenbaum, MD

“Steroid toxicity is rampant and it can be fatal… bringing it onto the radar screen of the practicing physician is really, really important.”   James T. Rosenbaum M.D. fell into ophthalmology by ...

Read More

The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time

Coping with steroid-toxicity has become an integral part of the treatment experience for patients with inflammatory disease for more than 70 years. With the development of new immunomodulatory ...

Read More

Making the case for steroid-sparing biologics on World Asthma Day

World Asthma Day was celebrated around the world on May 3rd - a day set aside to raise awareness about asthma and how those battling the condition can best equip themselves. This year, the Global ...

Read More
Featured

First new-drug approval in a decade for ANCA-associated vasculitis tackles steroid-toxicity

In October 2021, the US Food and Drug Administration issued its first new drug approval for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in a decade. The first-in-class ...

Read More